Expression of Bmi-1, p16, and CD44v6 in uterine cervical carcinoma and its clinical significance

Cancer Biology and Medicine

Volumn 9, Issue 1, 2012, Pages 48-53

  Weng, Mei Ying ^a   Li, Lin ^a   Feng, Shu Ying ^a   Hong, Shun Jia ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bmi 1 protein; CD44v6; Immunohistochemistry; P16 protein; Uterine cervical carcinoma

Indexed keywords

BMI1 PROTEIN; CD44V6 ANTIGEN; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX MUCOSA;

EID: 84876301027     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.01.009     Document Type: Article

References (12)

1. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 20: 845-54.
2. Haupt Y, Alexander WS, Barri G, et al. Novel zinc fin-gergene implicated asmyc collaboratorby retrovirally ac-celerated lymphomagenesis in Eμ-myctransgenic mice. Cell 1991; 65: 753-763.
3. Kikuchi J, Kinoshita I, Shimizu Y, et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010; 116: 3015-24.
4. Li DW, Tang HM, Fan JW, et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010; 136: 997-1006.
5. Honig A, Weidler C, Häusler S, et al. Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res 2010; 30: 1559-1564.
6. Guo BH, Feng Y, Zhang R, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011; 10: 10.
7. Song LB, Zeng MS, LiaoWT, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
8. Liu JH, Song LB, Zhang X, et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008; 97: 267-272.
9. Liggett WH Jr and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197-206.
10. Kawano T, Yanoma S, Nakamura Y, et al. Evaluation of soluble adhesion molecules CD44 (CD44 st, CD44 v5, CD44 v6), ICAM21, and VCAM21 as tumor markers in head and neck cancer. Am J Otolaryngol 2005; 26: 308-313.
11. Narayan G and Murty VV. Integrative genomic approaches in cervical cancer: Implications for molecular pathogenesis. Future Oncol 2010; 6: 1643-1652.
12. Yamazaki T, Tomita S, Ichikawa K, et al. P16-immunostaining pattern as a predictive marker of lymph node metastasis and recurrence in early uterine cervical cancer. Pathobiology 2006; 73: 176-182.